TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06122584: Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Sponsor: ABX advanced biochemical compounds GmbH · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 434 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,464,760

Rescue Site Savings

+$8,200,500

Unlock Full NCT06122584 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06122584 Rescue Dossier →